OGEN insider transaction filings
ORAGENICS INC — 24 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-07. Screen OGEN transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 1 Form 4 filing. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 1.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Spencer John — Chief Financial Officer | 1 | — | — | 1 |
Recent Form 4 filings — ORAGENICS INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-07 | 4 | Spencer John — Chief Financial Officer | Grant/award (A): 55,900 (derivative) @ $0 | EDGAR |
| 2026-01-22 | 4/A | Telling Fred — Director | Sale (S): 210 @ $0.94 · Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | Huffman Janet — CEO and CFO | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | Telling Fred — Director | Sale (S): 210 @ $0.94 · Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | Giordano Natasha — Director | Grant/award (A): 38,320 (derivative) @ $0 · Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | DUNTON ALAN W — Director | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | KOSKI ROBERT C — Director | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | GANDOLFO JOHN P — Director | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | POPE CHARLES L — Director | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Odyssey Health, Inc. — 10% owner | Sale (S): 2,000 @ $4.46 · Sale (S): 5,044 @ $4.26 | EDGAR |
| 2025-06-16 | 4 | Odyssey Health, Inc. — 10% owner | Sale (S): 5,000 @ $4.27 · Sale (S): 5,000 @ $4.45 | EDGAR |
| 2024-12-13 | 4 | KOSKI ROBERT C — Director | Conversion (C): 5,000 · Conversion (C): 1,500,000 (derivative) | EDGAR |
| 2024-12-09 | 4 | DUNTON ALAN W — Director | Sale (S): 66 @ $0.36 | EDGAR |
| 2024-12-09 | 4 | Telling Fred — Director | Sale (S): 3,597 @ $0.36 | EDGAR |
| 2024-09-20 | 4 | Telling Fred — Director | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2024-09-20 | 4 | REDMOND J MICHAEL — President | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-09-20 | 4 | POPE CHARLES L — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-09-20 | 4 | KOSKI ROBERT C — Director | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2024-09-20 | 4 | Huffman Janet — Chief Financial Officer | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2024-09-20 | 4 | GANDOLFO JOHN P — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2024-09-20 | 4 | DUNTON ALAN W — Director | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2024-09-20 | 4 | Cassidy Bruce A. Sr. — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2024-09-20 | 4 | Murphy Kimberly M — Director | Grant/award (A): 27,083 (derivative) @ $0 | EDGAR |
| 2024-01-02 | 4 | REDMOND J MICHAEL — President | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — ORAGENICS INC
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-16 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-28 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-19 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-13 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-31 | 8-K | ? 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-11 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-20 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=OGEN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →